Lexaria Bioscience Corp. (LEXX) Income Statement
LEXX FY2025 at a glance
Fiscal year ended August 31, 2025 · U.S. dollarsLEXX revenue and net income
Where LEXX's revenue goes
FY2025Each bar shows an amount and its share of revenue. LEXX kept −1,686.0% of revenue as net income.
LEXX profit margins
LEXX growth rates
to FY2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +52.0% | +40.3% | +12.9% | +47.3% |
| Gross profit | +53.1% | +56.5% | +26.7% | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
LEXX quarterly EPS vs estimates
Lexaria Bioscience beat the analyst EPS estimate in 4 of the last 8 quarters. Next report: November 25, 2026 (estimate $-0.90).
LEXX income statement
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $705,923 | $464,278 | $226,208 | $255,397 | $722,738 | $384,543 | $222,610 | $433,287 | $63,639 | $40,718 |
| Cost of revenue | $2,720 | $4,822 | $31,500 | $71,841 | $175,346 | $99,378 | $22,893 | $25,185 | $29,750 | $45,615 |
| Gross profit | $703,203 | $459,456 | $194,708 | $183,556 | $547,392 | $215,415 | $199,717 | $408,102 | $33,889 | −$4,897 |
| Research & development | $8.2M | $2.4M | $3.7M | $1.8M | $1.3M | $387,074 | $555,730 | $492,864 | $54,185 | $9,024 |
| Sales, general & admin | $4.3M | $3.9M | $3.1M | $5.0M | $5.0M | $4.0M | $3.6M | $6.5M | $1.8M | $1.2M |
| Total operating expenses | $12.6M | $6.2M | $6.7M | $6.8M | $6.2M | $4.4M | $4.3M | $7.0M | $1.9M | $1.2M |
| Operating income | −$11.9M | −$5.8M | −$6.5M | −$6.6M | −$5.7M | −$4.1M | −$4.1M | −$6.6M | −$1.9M | −$1.2M |
| Interest income | $3,017 | $14,311 | $43,190 | $0 | — | — | — | — | — | — |
| Interest expense | — | — | — | $114,329 | $0 | $0 | $0 | $0 | $6,015 | $2,250 |
| Income before taxes | −$11.9M | −$5.8M | −$6.7M | −$7.4M | −$4.2M | −$4.1M | −$4.2M | −$6.6M | −$1.9M | −$1.3M |
| Income taxes | — | — | $130,877 | −$114,329 | −$1.7M | −$54,286 | $39,623 | −$8,968 | −$54,173 | −$60,226 |
| Net income | −$11.9M | −$5.8M | −$6.7M | −$7.3M | −$4.0M | −$3.9M | −$4.1M | −$6.6M | −$1.9M | −$1.2M |
| EBITDA | −$11.8M | −$5.7M | −$6.6M | −$7.3M | −$4.0M | −$4.0M | −$4.0M | −$6.6M | −$1.9M | −$1.3M |
| EPS (diluted) | −$0.66 | −$0.47 | −$1.01 | −$1.25 | −$0.84 | −$0.05 | −$0.04 | −$0.10 | −$0.49 | −$0.80 |
| Gross margin | 99.6% | 99.0% | 86.1% | 71.9% | 75.7% | 56.0% | 89.7% | 94.2% | 53.3% | −12.0% |
| Operating margin | −1,683.0% | −1,239.2% | −2,888.5% | −2,591.7% | −786.8% | −1,078.9% | −1,823.7% | −1,523.3% | −2,914.6% | −3,023.1% |
| Net margin | −1,686.0% | −1,248.2% | −2,946.4% | −2,846.3% | −557.2% | −1,023.0% | −1,841.5% | −1,523.0% | −2,937.3% | −2,983.4% |
| May '26 | Feb '26 | Nov '25 | Aug '25 | May '25 | Feb '25 | Nov '24 | Aug '24 | May '24 | Feb '24 | Nov '23 | Aug '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $20,000 | $0 | $174,000 | $174,000 | $174,000 | $183,923 | $84,000 | $84,000 | $145,000 | $151,278 | $0 |
| Cost of revenue | $0 | $26,568 | $24,197 | $21,398 | $15,422 | $17,809 | $2,720 | $16,370 | $15,074 | $15,931 | $4,822 | $56,173 |
| Gross profit | $0 | $20,000 | −$24,197 | $174,000 | $174,000 | $174,000 | $181,203 | $84,000 | $84,000 | $145,000 | $146,456 | −$3,433 |
| Research & development | $970,834 | $475,388 | $671,340 | $1.9M | $2.7M | $1.7M | $2.0M | $967,206 | $573,089 | $245,779 | $574,491 | $500,406 |
| Sales, general & admin | $1.0M | $996,515 | $902,291 | $980,477 | $1.2M | $1.2M | $918,690 | $1.3M | $1.3M | $583,157 | $711,107 | $566,673 |
| Total operating expenses | $2.0M | $1.5M | $1.6M | $2.9M | $3.9M | $2.9M | $2.9M | $2.3M | $1.8M | $813,005 | $1.3M | $1.1M |
| Operating income | −$2.0M | −$1.5M | −$1.6M | −$2.7M | −$3.8M | −$2.8M | −$2.7M | −$2.2M | −$1.7M | −$668,005 | −$1.1M | −$1.1M |
| Interest income | $837 | $1,769 | $12 | $2,816 | $190 | $0 | $11 | $6,993 | $0 | — | $7,319 | — |
| Interest expense | — | — | — | — | — | — | — | — | — | $1 | — | — |
| Income before taxes | −$2.0M | −$1.5M | −$1.6M | −$2.7M | −$3.8M | −$2.7M | −$2.7M | −$2.2M | −$1.8M | −$652,733 | −$1.2M | −$1.2M |
| Income taxes | $14 | $2,598 | $1,791 | — | — | $3,760 | — | — | −$2,623 | −$3,195 | $40,181 | −$9,696 |
| Net income | −$2.0M | −$1.4M | −$1.6M | −$2.7M | −$3.8M | −$2.7M | −$2.7M | −$2.2M | −$1.8M | −$649,539 | −$1.2M | −$1.2M |
| EBITDA | −$2.0M | −$1.4M | −$1.6M | −$2.7M | −$3.8M | −$2.7M | −$2.7M | −$2.2M | −$1.8M | −$636,801 | −$1.2M | −$1.2M |
| EPS (diluted) | −$0.08 | −$0.06 | −$0.07 | −$0.14 | −$0.21 | −$0.15 | −$0.16 | −$0.15 | −$0.13 | −$0.06 | −$0.13 | −$0.12 |
| Gross margin | — | 100.0% | — | 100.0% | 100.0% | 100.0% | 98.5% | 100.0% | 100.0% | 100.0% | 96.8% | — |
| Operating margin | — | −7,259.5% | — | −1,545.2% | −2,155.4% | −1,581.0% | −1,463.0% | −2,622.7% | −2,074.9% | −460.7% | −753.0% | — |
| Net margin | — | −7,249.9% | — | −1,549.3% | −2,177.6% | −1,559.3% | −1,470.0% | −2,600.9% | −2,121.1% | −448.0% | −779.6% | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in LEXX's financial statements (latest annual report filed November 28, 2025); data from EODHD. Sales, general & administrative expenses include sales and marketing.
LEXX financial results
In fiscal year 2025 (ended August 31, 2025), Lexaria Bioscience reported revenue of $0.7 million, up 52.0% from the year before. It had a net loss of $11.9 million, a net profit margin of −1,686.0%. Diluted earnings per share came to −$0.66. Over five years revenue grew at an average rate of 12.9% a year.
See the LEXX stock overview for the latest quote and news, or the LEXX chart for price history and technical indicators.
LEXX income statement FAQ
What is Lexaria Bioscience's annual revenue?
Lexaria Bioscience reported total revenue of $0.7 million for fiscal year 2025, which ended on August 31, 2025. That was up 52.0% from $0.5 million the previous year.
Is Lexaria Bioscience profitable?
No. Lexaria Bioscience reported a net loss of $11.9 million in fiscal 2025, a net profit margin of −1,686.0%; its operating margin was −1,683.0%.
What is Lexaria Bioscience's gross margin?
Lexaria Bioscience's gross margin was 99.6% in fiscal 2025: for every $100 of revenue, Lexaria Bioscience kept $100 after the direct cost of its products and services.
How much does Lexaria Bioscience spend on research and development?
Lexaria Bioscience spent $8.2 million on research and development in fiscal 2025, 1,167.1% of revenue.
How fast is Lexaria Bioscience growing?
Revenue grew 12.9% a year on average over the last five fiscal years, from $0.4 million to $0.7 million.
What are Lexaria Bioscience's earnings per share?
Lexaria Bioscience earned $-0.66 per diluted share in fiscal 2025, compared with $-0.47 a year earlier.
When will Lexaria Bioscience report its next earnings?
Lexaria Bioscience is expected to report results for the quarter ending August 31, 2026 on November 25, 2026.
When does Lexaria Bioscience's fiscal year end?
Lexaria Bioscience's fiscal year ends in August. The latest annual report covers the year ended August 31, 2025 and was filed on November 28, 2025.